FDA’s drug abuse advisory panel declines to back a general policy saying ibogaine is safe

Copyright 1993 Predicasts, a Division of Ziff Communications Co.
Faulkner & Gray, Inc.

Health Business

August 27, 1993

SECTION: No. 34, Vol. 8; ISSN: 0888-9805

LANGUAGE: ENGLISH

LENGTH: 198 words

HEADLINE: Briefly Noted

BODY: Allied Clinical Labs says it’s been told to expect a subpoena from HHS in connection with a probe by the agency of allegedly false or improper Medicare claims. The lab chain says it believes its own practices are legal . . . FDA has scheduled a Sept. 8 advisory panel meeting on switching the Syntex drug Naprosyn to OTC sales. The move may mean FDA will approve the drug in the near future, contrary to Wall Street expectations, says Mabon Securities analyst James Keeney. The agency also has scheduled a Sept. 9 panel meeting to review OTC Tagamet, but Merck’s OTC Pepcid isn’t on the agenda, Keeney says. . . .Ultrasound manufacturer ATL is cutting its work force by 240 people, or 11 percent. . . .The Health Research Group urges FDA to seek criminal charges against Eli Lilly over alleged defects in its Lifepak defibrillators. . . .FDA’s drug abuse advisory panel declines to back a general policy saying ibogaine is safe enough to be tested to see if it helps heroin and cocaine abusers kick their habits. . . .Columbia Hospital Corp. says FTC has given a green light to its merger with Galen.

Print Friendly

Comments are closed